The X-sight spine tracking system was integrated with Cyberknife unit to deliver radiosurgery treatments for spinal tumors without fiducial placement. However the tracking system can also be used for the treatment of abdominal tumors located in a certain distance from the spine. The aim of our study is to evaluate the tracking performance of the X-sight spine system for abdominal tumors distal to spine based on the 3 factors: tumor distance from the reference vertebra, the angle of tumor with the vertebra, and the amplitude of tumor motion due to respiration. An experimental setup was designed mainly with ovine lumbar vertebrae and the BrainLab ExacTrac gating phantom. Planning Target Volume (PTV) structures were delineated at different vertical distances from the reference vertebra. The dosimetric measurements were taken with GafChromic EBT3 film placed between slab phantoms so that they corresponded to centers of the target volumes. Dosimetric comparisons were performed based on dose-volume parameters and the gamma analysis. The measurements were then repeated for the same experimental conditions by using the Synchrony system to compare tracking performances. Using the X-sight system, percentage differences between the dose-volume parameters of the Treatment Planning System (TPS) calculations and the EBT3 film readings went up to 12% for the motion amplitude of 8 mm. The differences decreased with small motions while angles and vertical distances of the lesion locations did not induce major changes in dose discrepancies. Percentages of pixels passing gamma analysis were found to be below the acceptance threshold of 95%. Using the Synchrony system, the measured dose distributions had more similar patterns with those of the TPS system such that the percentage differences in the dose parameters were less than 4% and the gamma passing rates were found to be higher than 95%. Our results showed that the X-sight spine system should not be chosen for tracking abdominal tumors distal to the spine or osseous structures because of the effect of diaphragmatic motion on entire abdominal region. The fiducial-based Synchrony tracking system can be preferred for these tumors.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.meddos.2019.01.003 | DOI Listing |
J BUON
March 2020
1Dr Lutfi Kirdar Kartal Training and Research Hospital, Department of Radiation Oncology, Istanbul, Turkey.
Purpose: To determine local control and overall survival of patients with medically inoperable early-stage non-small cell lung cancer (NSCLC) treated with stereotactic ablative radiotherapy.
Methods: Included were a total of 52 patients (7;13% females and 45;87% males) with medically inoperable early-stage NSCLC and who were treated with stereotactic ablative body radiotherapy (SBRT) by a CyberKnife robotic radiotherapy machine between 2009 and 2017. Depending on tumor size and location, median 45 Gy (30-60) were delivered in median 3 fractions (3-5) to Planning Target Volume.
Med Dosim
April 2020
Hacettepe University Faculty of Medicine, Department of Radiation Oncology, Ankara 06100, Turkey.
The X-sight spine tracking system was integrated with Cyberknife unit to deliver radiosurgery treatments for spinal tumors without fiducial placement. However the tracking system can also be used for the treatment of abdominal tumors located in a certain distance from the spine. The aim of our study is to evaluate the tracking performance of the X-sight spine system for abdominal tumors distal to spine based on the 3 factors: tumor distance from the reference vertebra, the angle of tumor with the vertebra, and the amplitude of tumor motion due to respiration.
View Article and Find Full Text PDFFront Oncol
July 2015
Drexel University College of Medicine, Philadelphia, PA , USA ; Philadelphia CyberKnife , Philadelphia, PA , USA.
Introduction: Stereotactic ablative body radiotherapy (SABR) provides a superior non-small cell lung cancer (NSCLC) treatment option when compared to conventional radiotherapy for patients deemed inoperable or refusing surgery. This study retrospectively analyzed the rates of tumor control and toxicity following SABR treatment (Cyberknife system) of primary early-stage NSCLC in a community setting.
Methods: One hundred patients were treated between 2007 and 2011.
Front Oncol
August 2012
Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA.
This retrospective analysis examines the local control and toxicity of five-fraction fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body (VB) metastases. All patients had favorable performance status (ECOG 0-1), oligometastatic disease, and no prior spine irradiation. A prescribed dose of 30-35 Gy was delivered in five fractions to the planning target volume (PTV) using the CyberKnife with X-sight spine tracking.
View Article and Find Full Text PDFChin J Cancer
September 2010
Department of Radiation Oncology, Nanjing General Hospital of Nanjing Military Command, Nanjing, Jiangsu 210002, PR China.
Background And Objective: CybeKnife is a newly developed technology in the field of stereotactic radiosurgery/radiotherapy (SRS/SRT). Compared with conventional SRS/SRT, there are many advantages for CyberKnife in terms of treating tumors that move with respiration, being real-time image-guidance, frameless, high accurateness, and so on. Recently, it has been used to treat different types of malignant carcinoma including intracranial and caudomedial tumors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!